Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Dova Pharmaceuticals
Dova Pharmaceuticals
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
Tue, 10/8/19 - 10:53 am
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it
Endpoints
Mon, 09/30/19 - 12:06 pm
Dova Pharmaceuticals
Eisai
Swedish Orphan Biovitrum
M&A
3 Small-Cap Biotech Stocks That Soared Last Week
Motley Fool
Mon, 07/1/19 - 10:27 am
Dova Pharmaceuticals
Doptelet
Krystal Biotech
KB103
MeiraGTx
gene therapy
AAV-RPE65
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
Mon, 06/24/19 - 07:27 pm
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Thu, 05/30/19 - 09:39 am
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Salix arms its GI salesforce with 2nd liver treatment in Doptelet co-promotional deal
Fierce Pharma
Fri, 10/5/18 - 12:09 pm
Salix
Dova Pharmaceuticals
Doptelet
FDA
chronic liver disease
FDA approves first TPO agonist for chronic liver disease
Biopharma Dive
Tue, 05/22/18 - 11:30 am
FDA
Dova Pharmaceuticals
Doptelet
chronic liver disease
thrombocytopenia
Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul
Endpoints
Thu, 06/29/17 - 02:22 pm
IPOs
biotech
Dova Pharmaceuticals
Mersana
Aileron